Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib works as first-line therapy in
treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer.